Compare Regeneron Pharmaceuticals Inc (REGN) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Financial Select Sector SPDR Fund — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Financial Select Sector SPDR Fund trades at $56.08. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Financial Select Sector SPDR Fund pays none, and Financial Select Sector SPDR Fund is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | XLF | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | — |
52-Week High | $812.27 | $56.75 |
52-Week Low | $545.46 | $47.80 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
XLF trades at $56.04, down 0.39% today, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF holds 76 financial companies and benefits from strong bank earnings, with recent news highlighting its low expense ratio of 0.08% and exposure to diversified financials. Geopolitical tensions and potential Federal Reserve rate hikes are key market drivers.
Outlook remains positive due to robust sector earnings and potential rate hike benefits, though risks include geopolitical volatility and high investor expectations. Wall Street sentiment is cautiously optimistic, with technical support near $56.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
